C
VRTX icon

CFO4Life’s Vertex Pharmaceuticals VRTX Stock Holding History

CFO4Life’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$543K Buy
+1,879
New +$573K 0.12% 100

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

CFO4Life's VRTX Position: Q4 2022 in Review

CFO4Life opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2022: 1,879 shares worth $543K. The stake represents 0.12% of the portfolio and ranks #100 among its holdings.

1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • CFO4Life held 1,879 shares of Vertex Pharmaceuticals worth $543K as of Q4 2022.
  • Vertex Pharmaceuticals was a new CFO4Life position in Q4 2022.
  • Vertex Pharmaceuticals made up 0.12% of CFO4Life's portfolio in Q4 2022, its #100 holding.
  • 1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on CFO4Life's 13F filing for Q4 2022, filed 11 Jan 2023.